Date: 2014-03-17
Type of information: Nomination
Compound: member of the board of directors
Company: Fate Therapeutics (USA - CA)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 17, 2014, Fate Therapeutics, a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
Dr. Epstein is a strategic consultant to life sciences companies and an epidemiologist with extensive expertise in pharmacoeconomics and health outcomes research, having held various positions in academia and public health before joining the private sector. From 2010 to 2012, Dr. Epstein served as president of the Medco-UBC Division and as Chief Research and Development officer of Medco Health Solutions, Inc., a managed healthcare company. In these roles, Dr. Epstein was responsible for all of Medco's clinical research initiatives, including the Medco Research Consortium and United BioSource Corporation. Dr. Epstein served as Medco's Chief Medical Officer from 1997 to 2010, leading formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting.
- Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life, and was also elected to the AHRQ CERT (Centers for Education and Research on Therapeutics) Committee. In addition to Fate Therapeutics, Dr. Epstein serves on the Board of Directors of Illumina, AVEO Pharmaceuticals, and Proteus Digital Health.
Financial terms:
Latest news:
Is general: Yes
